Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion
Safety and Efficacy of Endovascular Treatment for Progressive Stroke Due to Vertebrobasilar Artery Occlusion: A Multicenter, Prospective, Open-Label Randomized Controlled Trial With Blinded Endpoint Assessment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Feng Gao, MD
- Phone Number: 13581936066
- Email: gaofengletter@sina.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of <10 at initial symptom onset, and no prior endovascular treatment.
- Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline.
- Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA.
- Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of ≤3 on CT or diffusion-weighted imaging (DWI).
- Randomization within 24 hours of stroke progression.
- Pre-stroke mRS score of 0-2.
- Provision of signed informed consent by the patient or their legal representative.
Exclusion Criteria:
- Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging.
- Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes.
- Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging.
- Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms <3 mm in diameter), or intracranial arteriovenous malformation.
- Known or highly suspected chronic responsible artery occlusion.
- Presence of severe stenosis in the extracranial or intracranial segment of the responsible artery, arterial dissection, or excessive vascular tortuosity that may prevent successful delivery or navigation of endovascular devices.
- Known contraindication to contrast medium (except mild rash).
- Refractory hypertension not controlled by medication, defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg.
- Known pregnancy or lactation, or a positive pregnancy test prior to randomization.
- Known dementia or psychiatric disease precluding completion of neurological assessment and follow-up.
- Life expectancy <1 year, including patients with malignancy or advanced cardiopulmonary disease.
- Current participation in any other clinical trial of drugs or medical devices, or anticipated participation in another such trial within 3 months after enrollment.
- Acute ischemic stroke within 48 hours after cardiovascular or cerebrovascular interventional treatment or major surgery; patients presenting >48 hours after such procedures were eligible.
- Recent (within 1 month) gastrointestinal or genitourinary bleeding, acute myocardial infarction, or traumatic brain injury.
- Multivessel severe stenosis or occlusion confirmed by CTA, MRA, or DSA.
- Known or suspected central nervous system vasculitis.
- Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, current use of oral anticoagulants with an INR >1.5, or active bleeding.
- Blood glucose <2.8 or >22.2 mmol/L; platelet count <100 × 10⁹/L; estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² or serum creatinine ≥177 μmol/L (2.0 mg/dL).
- Any other condition deemed by the site investigator to make the patient unsuitable for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Endovascular Treatment Group
Participants randomized to the endovascular recanalization arm will receive endovascular treatment in addition to medical therapy.
The procedure aims to achieve recanalization of the occluded vertebrobasilar artery using mechanical thrombectomy techniques, including stent retriever and/or aspiration-based approaches.
When necessary, adjunctive endovascular measures may be performed as rescue therapy at the discretion of the treating neurointerventionalists.
|
The endovascular approach is selected by the treating neurointerventionalists based on angiographic findings, occlusion characteristics, and procedural feasibility.
Permitted techniques include mechanical thrombectomy using stent retriever and/or aspiration-based methods.
Adjunctive endovascular procedures, such as balloon angioplasty, stent deployment, or intraarterial thrombolysis, may be used when deemed necessary to achieve or maintain vessel patency.
Angiographic reperfusion is assessed during the procedure, and treatment is terminated once adequate revascularization is obtained.
Subsequent medical therapy is individualized according to stroke mechanism, procedural findings, and post-treatment imaging.
|
|
Experimental: Medical Therapy Alone Group
Participants randomized to this arm will receive medical therapy alone, consistent with current guideline recommendations for the acute and secondary prevention phases of ischemic stroke.
No endovascular recanalization procedures are permitted after randomization.
|
Medical therapy consists of comprehensive evidence-based medical therapy for acute ischemic stroke, encompassing acute supportive care, neurological and physiological monitoring, etiological evaluation, and secondary prevention strategies.
Standard pharmacological treatments are administered as appropriate, together with risk factor modification and supportive care measures, in accordance with current guideline recommendations.
Endovascular recanalization procedures are not included in this treatment strategy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of patients achieving modified Rankin Scale (mRS) score 0-3 at 90 days
Time Frame: 90±14 days after randomization
|
The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death.
|
90±14 days after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ordinal shift analysis of mRS score at 90 days after randomization
Time Frame: 90±14 days after randomization
|
The modified Rankin Scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.
|
90±14 days after randomization
|
|
The proportion of patients achieving mRS scores 0-1 and 0-2 at 90 days
Time Frame: 90±14 days after randomization
|
The modified Rankin Scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.
|
90±14 days after randomization
|
|
The National Institutes of Health Stroke Scale (NIHSS) score at 24 hours
Time Frame: 24 (-6/+12) hours after randomization
|
National Institutes of Health Stroke Scale (NIHSS) score at 24 hours after randomization The National Institute of Health Stroke Scale (NIHSS) ranged from 0 to 42, with higher scores indicating greater neurologic deficits.
|
24 (-6/+12) hours after randomization
|
|
The NIHSS score at 7 days after randomization or discharge (whichever came first), as well as changes from baseline
Time Frame: 7 days after randomization or at discharge
|
NIHSS score at 7 days after randomization or discharge (whichever came first) The National Institute of Health Stroke Scale (NIHSS) ranged from 0 to 42, with higher scores indicating greater neurologic deficits.
|
7 days after randomization or at discharge
|
|
The score on the European Quality of life 5-Dimension 5-Level (EQ-5D-5L) patient-reported questionnaire score at 90 days
Time Frame: 90±14 days after randomization
|
European Quality of life 5-Dimension 5-Level (EQ-5D-5L) is a standardized instrument for measuring the general health status.
Rated level can be coded as a number 1, 2, 3, 4 or 5, which indicates having no problems for 1, having some problems for 2, having moderate problems for 3, having serious problems for 4 and having extreme problems for 5.
|
90±14 days after randomization
|
|
The proportion of Barthel index 95-100 points at 90 days
Time Frame: 90±14 days after randomization
|
The proportion of Barthel Index 95-100 at 90 days after randomization.
|
90±14 days after randomization
|
|
The recanalization of the vertebrobasilar artery at 24 hours after randomization (confirmed by CTA, MRA, DSA, or TCD)
Time Frame: 24 (-6/+12) hours after randomization
|
The recanalization of the vertebrobasilar artery at 24 hours after randomization (confirmed by CTA, MRA, DSA or TCD).
|
24 (-6/+12) hours after randomization
|
|
The rate of technical success is defined as the successful recanalization of the target vessel at the end of the procedure (expanded Thrombolysis in Cerebral Infarction scale [eTICI] 2b-3)
Time Frame: At the end of the procedure
|
Technical success rate, defined as successful recanalization of target vessels at the end of procedure (The expanded Thrombolysis in Cerebral Infarction scale [eTICI] 2b-3).
|
At the end of the procedure
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of mortality within 90 days after randomization
Time Frame: 90±14 days after randomization
|
All-cause mortality within 90 days after randomization.
|
90±14 days after randomization
|
|
The incidence of any symptomatic intracranial hemorrhage (sICH) defined as the Heidelberg classification within 24 hours
Time Frame: 24 (-6/+12) hours after randomization
|
Heidelberg standard was defined as new intracranial hemorrhage detected by brain imaging associated with any of the item below: 4 points of total NIHSS score at the time of diagnosis compared to immediately before worsening.
2 points of NIHSS score in one category.
Leading to intubation/hemicraniectomy/ventricular drainage placement or other major medical/surgical intervention.
Absence of alternative explanation for deterioration.
|
24 (-6/+12) hours after randomization
|
|
The rate of any intracranial hemorrhage identified by CT or MRI imaging within 24 hours
Time Frame: 24 hours after randomization
|
Any intracranial hemorrhage identified by CT or MRI imaging within 24 hours.
|
24 hours after randomization
|
|
The rate of all-cause mortality within 7 days
Time Frame: 7 days after randomization or at discharge
|
The rate of all-cause mortality within 7 days after randomization.
|
7 days after randomization or at discharge
|
|
The incidence of procedure-related complications: arterial perforation, arterial dissection, and embolism in newly developed vascular areas
Time Frame: At the end of the operation or intraoperative
|
The incidence of procedure-related complications: arterial perforation, arterial dissection, and embolism in newly developed vascular areas.
|
At the end of the operation or intraoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Feng Gao, MD, Beijing Tiantan Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HX-A-2026012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.